TL;DR
- 1.Sermorelin was FDA-approved in 1997 (NDA 20-443) and prescribed to thousands of children with growth hormone deficiency for over a decade. The FDA withdrew approval in 2008 for commercial reasons, not safety. That prior approval makes sermorelin the only GHRH analog eligible for 503A compounding pathways today.
- 2.CJC-1295 has exactly one published human randomized controlled trial: Teichman et al., Journal of Clinical Endocrinology and Metabolism, 2006. A follow-up development program was discontinued after an unresolved cardiac signal. No Phase III trial has ever been completed.
- 3.In December 2024, the FDA Pharmacy Compounding Advisory Committee voted against adding CJC-1295 to the 503A bulks list, citing cardiotoxicity concerns and immunogenicity risk. No lawful US compounding pathway exists for CJC-1295 as of July 2026.
- 4.Sermorelin triggers pulsatile GH release that mirrors the body's own rhythm, which limits the risk of receptor desensitization. CJC-1295 with DAC creates a continuous GH floor over 6 to 9 days from a single injection, which amplifies short-term IGF-1 but raises questions about long-term receptor sensitivity that no multi-year human trial has answered.
- 5.Your GHR gene changes what both peptides can do. Carriers of the d3 deletion variant convert each GH pulse to IGF-1 roughly 1.5 to 2 times more efficiently. If you carry d3, sermorelin at the standard dose can produce IGF-1 responses in the same range that CJC-1295 achieves in fl/fl carriers.
Most peptide comparison articles open with a half-life chart. This one opens with a number: 1. That is the number of published randomized controlled human trials for CJC-1295. One. From 2006. And the follow-up development program that was supposed to run Phase II and III trials never completed them, because an unresolved cardiac signal ended CJC-1295's path as a pharmaceutical.
Sermorelin, by contrast, has a full FDA approval history. Not a pilot study. Not a Phase I trial in 66 healthy adults. A regulated approval under NDA 20-443, covering pediatric growth hormone deficiency, with clinical data spanning from 1997 through 2008. The evidence asymmetry between these two compounds is the most important thing nobody covers in sermorelin vs CJC-1295 comparisons. So we are going to cover it first.
The number of published randomized controlled human trials for CJC-1295. Sermorelin, by comparison, was FDA-approved with multi-year clinical trial data before CJC-1295 existed as a compound.
Think of GHRH analogs like a signal to your pituitary: "make growth hormone now." Sermorelin mimics the natural signal your hypothalamus sends every few hours. CJC-1295 with DAC is more like leaving that signal on for a week. Both can raise IGF-1. The question is which approach has the data to back up long-term safety, and the answer is not close.
How Many Years of Human Data Does Each Peptide Actually Have?
Sermorelin (GHRH 1-29) is the biologically active N-terminal fragment of endogenous growth hormone releasing hormone. It is not a modified or synthetic compound. It is the precise sequence your hypothalamus releases to signal the pituitary to fire a GH pulse. The FDA approved it in September 1997 under NDA 20-443, branded as Geref, for idiopathic growth hormone deficiency in children with growth failure.
The pivotal trials supporting that approval showed that daily subcutaneous sermorelin increased growth velocity in approximately 74% of treated children after 6 months, with data maintained through 36 months. That is not a proxy endpoint. That is measurable linear growth in pediatric patients, validated across multiple study sites, under full FDA review.
EMD Serono voluntarily withdrew Geref from the market in 2008. The Federal Register confirmed in March 2013 that the withdrawal was for commercial reasons, specifically the dominance of recombinant human growth hormone in the pediatric market, not for safety or efficacy concerns. The compound was not pulled because it stopped working or because it caused harm. It was pulled because rHGH made more money.
That prior FDA approval history is why sermorelin is currently eligible for 503A compounding. Licensed compounding pharmacies can prepare it for patient-specific prescriptions under a physician order. No other GHRH analog has this status.
CJC-1295: One Study, One Compound, One Abandoned Development Path
CJC-1295 was engineered to extend the half-life of the GHRH 1-29 sequence. The DAC (Drug Affinity Complex) moiety covalently binds serum albumin, extending half-life from roughly 10 minutes to 5.8 to 8.1 days. That is a genuinely impressive pharmacological feat. The company ConjuChem developed it and ran a Phase I/II trial published in the Journal of Clinical Endocrinology and Metabolism in 2006.
"A single injection of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was well-tolerated with no serious adverse events."
Teichman SL et al., Journal of Clinical Endocrinology and Metabolism, 2006
The Teichman trial enrolled 66 healthy adults aged 21 to 61. Single subcutaneous doses of 1 to 30 mcg/kg produced 2 to 10-fold GH elevation and 1.5 to 3-fold IGF-1 elevation, sustained for 9 to 11 days. Those are impressive numbers. Flushing, headache, injection-site reactions, and mild nausea appeared in a large share of participants, but no serious adverse events occurred in this trial.
Here is what that trial was never designed to answer: what happens to pituitary receptor sensitivity after 6, 12, or 24 months of weekly CJC-1295 injections? What does sustained, non-pulsatile GH elevation do to insulin sensitivity over time? The Teichman study ran for 49 days. It is a Phase I safety and pharmacokinetics study. It is not a long-term safety trial, and ConjuChem never completed one.
The maximum study duration in the only published human CJC-1295 clinical trial. Long-term receptor desensitization, metabolic effects, and sustained GH elevation consequences have never been studied in a human cohort beyond this window.
Is CJC-1295 Still Legal to Compound in the US?
No. As of July 2026, no lawful 503A or 503B compounding pathway exists for CJC-1295. On December 4, 2024, the FDA Pharmacy Compounding Advisory Committee voted against recommending CJC-1295 for inclusion on the 503A bulks list. The objections cited in the FDA briefing document included nonclinical toxicity findings, an unresolved cardiac signal from the abandoned post-2006 development program, and immunogenicity risk from the albumin-binding DAC moiety.
The cardiac concern is not a minor footnote. CJC-1295's clinical development was discontinued after the Phase I data. The FDA's December 2024 briefing made clear that the agency reviewed the full toxicology package that ConjuChem submitted and could not reconcile the cardiac signal. That is the finding that competitor comparison articles consistently omit.
| Factor | Sermorelin | CJC-1295 (with DAC) |
|---|---|---|
| FDA approval history | Yes (NDA 20-443, 1997-2008) | No |
| Published human RCTs | Multiple (FDA pivotal trials) | 1 (Phase I/II, 49 days) |
| Longest clinical follow-up | 36 months | 49 days |
| US 503A compounding status (July 2026) | Eligible (Category 1 bulks list) | Not eligible (PCAC voted against, Dec 2024) |
| Unresolved safety signal | None documented | Cardiac signal (cited in FDA Dec 2024 briefing) |
| Half-life | 10 to 20 minutes | 5.8 to 8.1 days |
| IGF-1 elevation per injection | Moderate, pulsatile | 1.5 to 3x baseline, sustained 9 to 11 days |
The practical consequence for anyone currently using or considering CJC-1295: any compounding pharmacy filling CJC-1295 prescriptions after December 2024 is operating without a lawful federal basis. Some continue to do so. That is their legal exposure, not yours as a patient, but it is a sign that the compound has no regulated quality standard applied to its preparation.
Pulsatile vs Sustained: Why This Distinction Matters for Long-Term Use
Sermorelin works the way your hypothalamus works. Each injection fires a short GH pulse that clears in 20 minutes, mimicking the natural oscillation of endogenous GHRH release. The pituitary receives a signal, fires GH, and the axis resets. This is also why it is nearly impossible to produce pathologically elevated GH with sermorelin: the feedback system remains intact.
CJC-1295 with DAC does something different. Because the DAC moiety keeps it circulating for up to 9 days, it creates a continuous GHRH signal at the pituitary. GH levels rise and stay elevated above baseline around the clock. That produces stronger IGF-1 elevation than sermorelin, which is the main argument clinics made for using it before 2024.
Mimics natural GHRH rhythm. GH pulse clears in 20 minutes. Feedback regulation intact. Receptor sensitivity preserved over time. 36-month human data available.
Continuous GH floor for 6 to 9 days per injection. Stronger short-term IGF-1 elevation. No multi-year human safety data. Receptor desensitization risk over long cycles is unknown.
The question the peptide community never gets a clean answer to is whether long-term sustained GH elevation through CJC-1295 desensitizes pituitary receptors or disrupts the feedback axis over 12 to 24 months. The answer is: nobody knows. There is no human study. What we do know from sermorelin's 36-month data is that pulsatile stimulation preserves long-term axis function. That is the only GHRH analog with that answer confirmed in humans.
If you want to understand the pharmacological detail on what the DAC moiety actually does to GH kinetics, the CJC-1295 with DAC vs without DAC breakdown covers the receptor mechanics in full. For sermorelin's dosing framework once you have decided to use it, the sermorelin dosage guide has a body-weight chart with IGF-1 titration protocol.
Your GHR Gene Changes Which of These Peptides Is Right for You
One finding that competitor comparisons consistently ignore: the GHR exon-3 deletion (d3) variant substantially changes the IGF-1 response to both peptides. Dos Santos et al., published in the Journal of Clinical Endocrinology and Metabolism in 2007, studied children with idiopathic short stature and found that d3GHR allele carriers showed statistically higher IGF-1 responses to GH-axis stimulation than fl/fl homozygotes (P=0.037).
In practical terms: if you carry one or two d3 alleles, your liver converts each GH pulse to IGF-1 more efficiently than the standard genotype. That means sermorelin, which generates pulsatile GH rather than a continuous floor, can produce IGF-1 elevations in d3 carriers that approach or match what CJC-1295 achieves in the general population. The dosing math changes entirely when genetics are in the picture.
GHRHR variants add another layer. The GHRH receptor at the pituitary governs how strongly any GHRH analog stimulates GH release. Reduced-function GHRHR variants blunt the response to both sermorelin and CJC-1295. If your GH axis is running against a GHRHR bottleneck, switching from sermorelin to CJC-1295 does not bypass the problem. It just creates the same flat IGF-1 result with a longer-acting compound that carries more regulatory and safety uncertainty.
The most common GH axis bottlenecks and which peptides they affect are covered in the ipamorelin and CJC-1295 genotype-based dosing guide. If you want bloodwork targets to assess where your bottleneck actually sits, the peptide bloodwork guide has the full panel and interpretation framework.
Who Should Still Consider CJC-1295 in 2026?
The honest answer is almost no one in the United States, because the legal supply chain for compounded CJC-1295 no longer has a regulatory basis. If you are outside the US in a jurisdiction without equivalent restrictions, and if you have access to verified pharmaceutical-grade product, the Teichman data is real and the IGF-1 response is real. The evidence gap is about long-term safety, not short-term efficacy.
For most users in 2026, the comparison has effectively resolved itself. Sermorelin is legally available through a physician's prescription from a licensed 503A compounding pharmacy. It has decades of safety data. It preserves pituitary feedback regulation. Its IGF-1 response is lower per injection than CJC-1295 with DAC, but in d3 carriers and with appropriate dosing, the gap closes considerably.
The stacking question is separate. Ipamorelin, which is a ghrelin receptor agonist rather than a GHRH analog, can be combined with sermorelin for a synergistic GH pulse in the same way it was historically combined with Mod GRF 1-29. That combination approach is the most direct replacement for the CJC-1295 plus ipamorelin stack that clinics were running before 2024. See the sermorelin peptide profile for the protocol framework.
Verdict: Sermorelin wins on evidence, safety history, and legal status. CJC-1295 wins on acute IGF-1 elevation, and almost nothing else in 2026.
Sermorelin's 25-year human track record, FDA prior approval history, and preserved pulsatile mechanism make it the default choice for anyone seeking a legal GHRH analog with documented long-term safety. CJC-1295's stronger short-term IGF-1 response cannot compensate for one published Phase I trial, an unresolved cardiac flag, and no viable US compounding pathway. If your goal is to raise IGF-1 sustainably and legally over a multi-month protocol, the choice in 2026 is straightforward.
Not sure which GH peptide fits your genotype? Upload your existing genetic data or order a DNA kit to see how your GHR d3 status and GHRHR variants affect your GH axis response profile.
Your DNA shapes how you respond to each of these.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
Is sermorelin the same as CJC-1295?
No. Both mimic GHRH and stimulate GH release at the pituitary, but they are structurally distinct compounds with completely different pharmacokinetics. Sermorelin is GHRH(1-29), the natural N-terminal GHRH fragment, with a half-life of 10 to 20 minutes. CJC-1295 adds amino acid substitutions and a DAC moiety that extends half-life to 5.8 to 8.1 days. The result is a different GH release pattern: pulsatile for sermorelin, sustained for CJC-1295 with DAC. They are not interchangeable.
Which has more clinical data, sermorelin or CJC-1295?
Sermorelin has substantially more human clinical data. It was FDA-approved in 1997 with multi-year pediatric clinical trials, including 36-month follow-up data from growth hormone deficiency studies. CJC-1295 has one published randomized controlled human trial from 2006 (Teichman et al., JCEM), lasting 49 days. ConjuChem did not complete Phase II or Phase III trials, and development was discontinued after an unresolved safety signal. There is no comparison.
Can CJC-1295 be legally prescribed in the US in 2026?
No. In December 2024, the FDA Pharmacy Compounding Advisory Committee voted against recommending CJC-1295 for the 503A compounding bulks list. The committee cited nonclinical cardiotoxicity findings, an unresolved cardiac signal from its discontinued development program, and immunogenicity risk. As of July 2026, no lawful 503A or 503B compounding pathway exists for CJC-1295 in the United States. Sermorelin remains on the Category 1 bulks list and is legally compoundable with a prescription.
Does sermorelin raise IGF-1 as much as CJC-1295?
Not per injection in most genotypes. CJC-1295 with DAC produces 1.5 to 3-fold IGF-1 elevation sustained for 9 to 11 days from a single injection, which exceeds what a single sermorelin dose achieves. However, daily sermorelin builds cumulative IGF-1 elevation over weeks, and carriers of the GHR d3 variant convert GH pulses to IGF-1 more efficiently, narrowing the gap considerably. The practical difference in IGF-1 outcome at 12 weeks of daily sermorelin versus weekly CJC-1295 is smaller than the single-injection comparison suggests.
Can you stack sermorelin with ipamorelin like CJC-1295 was stacked?
Yes. The CJC-1295 plus ipamorelin stack worked because CJC-1295 (or Mod GRF 1-29) provides GHRH-pathway stimulation while ipamorelin provides ghrelin-receptor stimulation, and the two pathways are synergistic for GH pulse amplitude. Sermorelin occupies the same GHRH role. Daily or twice-daily sermorelin plus ipamorelin produces a similar synergistic GH pulse on the same pharmacological basis, and this combination has no equivalent regulatory barriers.
How does my GHR gene affect whether sermorelin or CJC-1295 works for me?
The GHR exon-3 deletion (d3) variant significantly amplifies IGF-1 output per unit of GH exposure. Dos Santos et al. (JCEM 2007) found d3 carriers showed statistically higher IGF-1 responses to GH-axis stimulation versus fl/fl carriers. In practical terms, d3 carriers on sermorelin may achieve IGF-1 elevations that approach what CJC-1295 produces in non-carriers. GHRHR variants additionally affect how strongly any GHRH analog stimulates GH release at the pituitary. Your PeptidesDNA report covers both markers.
What happened to the longer CJC-1295 clinical trials that were planned?
ConjuChem's CJC-1295 development program did not advance beyond the 2006 Phase I/II study. The company discontinued development of the compound before completing Phase II or Phase III trials. The FDA's December 2024 briefing document for the PCAC meeting cited an unresolved cardiac signal from that discontinued program as one of the committee's core safety concerns. The clinical development path was abandoned, not paused, which is why no long-term human safety data exists for CJC-1295.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.